MiR-27a regulates Wnt/beta-catenin signaling through targeting SFRP1 in glioma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioma is a prevalent and aggressive intracranial tumor with a poor prognosis.
• Wnt/beta-catenin signaling pathways are implicated in glioma development and progression.
• SFRP1 is a known antagonist of Wnt signaling, crucial in regulating cellular processes.

Purpose of the Study:

• To investigate the role of microRNA-27a (miR-27a) as an antineoplastic factor in glioma.
• To determine if miR-27a inhibits glioma progression by targeting the Wnt/beta-catenin pathway via SFRP1.
• To explore the therapeutic potential of miR-27a in glioma treatment.

Main Methods:

• Quantitative real-time PCR to assess miR-27a and SFRP1 expression levels.
• Western blot analysis to evaluate protein expression.
• Luciferase assay to confirm direct targeting of SFRP1 by miR-27a.
• In vitro studies on glioma cell lines to assess effects of miR-27a and SFRP1 manipulation on cell viability, cycle, apoptosis, and invasion/migration.

Main Results:

• miR-27a expression was found to be elevated in glioma samples and cell lines.
• Downregulation of miR-27a significantly inhibited glioma cell growth, induced cell cycle arrest, promoted apoptosis, and suppressed invasion/migration.
• SFRP1 was identified as a direct target of miR-27a, and its overexpression inhibited glioma malignancy.
• miR-27a was shown to suppress beta-catenin/TCF-4 transcriptional activity by targeting SFRP1.

Conclusions:

• miR-27a functions as a tumor suppressor in glioma by inhibiting the Wnt/beta-catenin signaling pathway through direct targeting of SFRP1.
• Modulating miR-27a levels offers a potential therapeutic strategy for managing glioma.
• These findings provide novel insights into the molecular mechanisms underlying glioma pathogenesis and treatment.